Effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus
https://doi.org/10.14341/DM2014134-40
Abstract
Introduction of drug-eluting stents for percutaneous coronary interventions opened novel options for treating coronary heart disease (CHD) in patients with diabetes mellitus. However, mortality and myocardial infarction rates are still higher among diabetes patients. They also require repeated revascularization of the target vessel more often than euglycemic individuals do. Current review discusses possible effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes.
About the Authors
Marina Sergeevna Michurova
Endocrinology Research Centre
Russian Federation
MD, clinical endocrinologist
Russian Federation
MD, clinical endocrinologist
Irina Vladimirovna Kononenko
Endocrinology Research Centre
Russian Federation
MD, PhD, Leading Researcher, Programm education and therapy department, Diabetes Institute
Russian Federation
MD, PhD, Leading Researcher, Programm education and therapy department, Diabetes Institute
Olga Mikhailovna Smirnova
Endocrinology Research Centre
Russian Federation
MD, PhD, Professor, Cheif Researcher, Programm Education and therapy department
Russian Federation
MD, PhD, Professor, Cheif Researcher, Programm Education and therapy department
Victor Yur'evich Kalashnikov
Endocrinology Research Centre
Russian Federation
MD, PhD, Head of Intervention cardiology department
Russian Federation
MD, PhD, Head of Intervention cardiology department
References
1. International Diabetes Federation, Diabetes Atlas, 5th ed.. 2011.
2. Davidson MH. Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. Am J Cardiol 2012;110(9 Suppl):43-49. doi: 10.1016/j.amjcard.2012.08.033.
3. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. Journal of the American College of Cardiology 2004;43(1):8-14. Available from: http://linkinghub.elsevier.com/retrieve/pii/S073510970301324X PubMed PMID: 14715174. doi: 10.1016/j.jacc.2003.06.019.
4. Cutlip DE. Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials. Circulation 2004;110(10):1226-1230. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.0000140721.27004.4B PubMed PMID: 15337693. doi: 10.1161/01.CIR.0000140721.27004.4B.
5. Flaherty JD. Diabetes and Coronary Revascularization. JAMA 2005;293(12):1501-1508. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.293.12.1501 PubMed PMID: 15784875. doi: 10.1001/jama.293.12.1501.
6. Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP, et al. Effect of Diabetes Mellitus on Five-Year Clinical Outcomes After Single-Vessel Coronary Stenting (a Pooled Analysis of Coronary Stent Clinical Trials. The American journal of cardiology 2006;98(6):718-721. Available from: http://dx.doi.org/10.1016/j.amjcard.2006.03.059 PubMed PMID: 16950169. doi: 10.1016/j.amjcard.2006.03.059.
7. Ruygrok PN, Webster, M. W.I, , de Valk V, van Es GA, Ormiston JA, Morel, M.-A. M, , et al. Clinical and Angiographic Factors Associated With Asymptomatic Restenosis After Percutaneous Coronary Intervention. Circulation 2001;104(19):2289-2294. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/hc4401.098294 PubMed PMID: 11696467. doi: 10.1161/hc4401.098294.
8. Stettler C. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 2006;92(5):650-657. Available from: http://heart.bmj.com/cgi/doi/10.1136/hrt.2005.070698 PubMed PMID: 16251229. doi: 10.1136/hrt.2005.070698.
9. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.. BMJ 2008;337:1131. Available from: http://www.bmj.com/cgi/pmidlookup?view=long&pmid=18757996 PubMed PMID: 18757996. doi: 10.1136/bmj.a1331.
10. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. Journal of the American College of Cardiology 2010;55(5):432-440. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109709034718 PubMed PMID: 20117456. doi: 10.1016/j.jacc.2009.10.014.
11. Dauerman HL. Percutaneous coronary intervention, diabetes mellitus, and death.. J Am Coll Cardiol 2010;55(11):1076-1079. Available from: http://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html PubMed PMID: 20079595. doi: 10.1016/j.jacc.2009.09.056.
12. Takara A, Ogawa H, Endoh Y, Mori F, Yamaguchi J, Takagi A, et al. Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovasc Diabetol 2010;9:1-1186. Available from: http://www.cardiab.com/content/9//1 PubMed PMID: 20047694. doi: 10.1186/1475-2840-9-1.
13. Indolfi C, Esposito G, Stabile E, Cavuto L, Pisani A, Coppola C, et al. A new rat model of small vessel stenting. Basic Research in Cardiology 2000;95(3):179-185. Available from: http://link.springer.com/10.1007/s003950050180 PubMed PMID: 10879619. doi: 10.1007/s003950050180.
14. Chronos NA, Goodall AH, Wilson DJ, Sigwart U, Buller NP. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation 1993;88(5):2035-2044. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.88.5.2035 PubMed PMID: 8222096. doi: 10.1161/01.CIR.88.5.2035.
15. Kolarov P, Tschope D, Nieuwenhuis HK, Gries FA, Strauer B, SchultheiB HP. PTCA: Periprocedural platelet activation Part II of the Duesseldorf PTCA Platelet Study (DPPS. European Heart Journal 1996 авг.;17(8):1216-1222. Available from: http://eurheartj.oxfordjournals.org/cgi/doi/10.1093/oxfordjournals.eurheartj.a015039 PubMed PMID: 8869863. doi: 10.1093/oxfordjournals.eurheartj.a015039.
16. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28(7):1643-1651. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=8962547 PubMed PMID: 8962547. doi: 10.1016/S0735-1097(96)00417-2.
17. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circulation Research 1993;73(3):589-595. Available from: http://circres.ahajournals.org/cgi/doi/10.1161/01.RES.73.3.589 PubMed PMID: 8348698. doi: 10.1161/01.RES.73.3.589.
18. Esposito K. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress. Circulation 2002;106(16):2067-2072. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.0000034509.14906.AE PubMed PMID: 12379575. doi: 10.1161/01.CIR.0000034509.14906.AE.
19. Zhang L. Diabetes-Induced Oxidative Stress and Low-Grade Inflammation in Porcine Coronary Arteries. Circulation 2003;108(4):472-478. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.0000080378.96063.23 PubMed PMID: 12860917. doi: 10.1161/01.CIR.0000080378.96063.23.
20. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proceedings of the National Academy of Sciences 1990;87(1):404-408. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.87.1.404 doi: 10.1073/pnas.87.1.404.
21. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients.. J Am Coll Cardiol 1996;27(3):528-535. Available from: http://www.nlm.nih.gov/medlineplus/diabetes.html PubMed PMID: 8606261. doi: dx.doi.org/10.1016/0735-1097(95)00496-3.
22. Aronson D. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Medical Hypotheses 2002;59(3):297-301. Available from: http://linkinghub.elsevier.com/retrieve/pii/S030698770200172X PubMed PMID: 12208156. doi: 10.1016/S0306-9877(02)00172-X.
23. Li X, Zhou S, Tang J, Liu Q, Fang Z, Hu X, et al. Changes of plasma CD40L and PAPP-A in patients with acute coronary syndrome after the PCI operation. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007;32(6):1098-1101. Available from: http://xbyx.xysm.net/xbwk/fileup/PDF/2007121098.pdf PubMed PMID: 18182735.
24. Szkodzinski J, Hudzik B, Romanowski W, Wilczek K, Danikiewicz A, Gasior M, et al. Serum concentration of insulin-like growth factor-I, but not tumor necrosis factor-alpha, measured twelve months after stenting of the infarct-related artery, is associated with in-stent restenosis. Journal of Biological Regulators & Homeostatic Agents 2010;24(2):149-156.
25. Bennett MR. IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS. Heart 2003;89(2):218-224. Available from: http://heart.bmj.com/cgi/doi/10.1136/heart.89.2.218 PubMed PMID: 12527687. doi: 10.1136/heart.89.2.218.
26. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32(7):1866-1873. Available from: http://ClinicalTrials.gov/search/term=9857865%20%5BPUBMED-IDS%5D PubMed PMID: 9857865. doi: -1097(98)00467-7.
27. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-444. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.16.2.434 PubMed PMID: 8432214. doi: 10.2337/diacare.16.2.434.
28. Ueda H, Mitsusada N, Harimoto K, Miyawaki M, Yasuga Y, Hiraoka H. Glycosylated Hemoglobin Is a Predictor of Major Adverse Cardiac Events after Drug-Eluting Stent Implantation in Patients with Diabetes Mellitus. Cardiology 2010;116(1):51-57. Available from: http://www.karger.com/doi/10.1159/000314331 PubMed PMID: 20453503. doi: 10.1159/000314331.
29. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. Journal of the American College of Cardiology 2004;43(1):8-14. Available from: http://linkinghub.elsevier.com/retrieve/pii/S073510970301324X PubMed PMID: 14715174. doi: 10.1016/j.jacc.2003.06.019.
30. Kassaian S, Goodarzynejad H, Boroumand M, Salarifar M, Masoudkabir F, Mohajeri-Tehrani M, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol 2012;11(1):82. Available from: http://www.cardiab.com/content/11/1/82 PubMed PMID: 22805289. doi: 10.1186/1475-2840-11-82.
31. Hasdai D, Rizza RA, Grill DE, Scott CG, Garratt KN, Holmes DR. Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization. American Heart Journal 2001;141(1):117-123. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002870301987411 PubMed PMID: 11136496. doi: 10.1067/mhj.2001.111957.
32. Kauffman AB, Delate T, Olson KL, Cymbala AA, Hutka KA, Kasten SL, et al. Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study. Clin Drug Investig 2008;28(8):501-507. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+50-78-2 PubMed PMID: 18598096. doi: 10.2165/00044011-200828080-00005.
33. Lindsay J, Sharma AK, Canos D, Nandalur M, Pinnow E, Apple S, et al. Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovascular Revascularization Medicine 2007;8(1):15-20. doi: 10.1016/j.carrev.2006.10.002.
34. Sullivan, C.J. O' , Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfik S, et al. Haemoglobin A1c (HbA1C) in Non-diabetic and Diabetic Vascular Patients. Is HbA1C an Independent Risk Factor and Predictor of Adverse Outcome. European Journal of Vascular and Endovascular Surgery 2006;32(2):188-197. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1078588406000578 PubMed PMID: 16580235. doi: 10.1016/j.ejvs.2006.01.011.
35. Lemesle G, Bonello L, de Labriolle A, Maluenda G, Syed AI, Collins SD, et al. Prognostic Value of Hemoglobin A1C Levels in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention With Stent Implantation. The American Journal of Cardiology 2009;104(1):41-45. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002914909006651 PubMed PMID: 19576319. doi: 10.1016/j.amjcard.2009.02.060.
36. Group, t.C.C.R.i.D.S. (Action) , Gerstein HC, Miller ME, Byington RP, Jr GDC, Bigger JT, et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358(24):2545-2559. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0802743 doi: 10.1056/NEJMoa0802743.
37. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008 июня;358(24):2560-2572. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0802987 doi: 10.1056/NEJMoa0802987.
38. Bayes-Genis A, Conover CA, Schwartz RS. The Insulin-Like Growth Factor Axis : A Review of Atherosclerosis and Restenosis. Circulation Research 2000;86(2):125-130. Available from: http://circres.ahajournals.org/cgi/doi/10.1161/01.RES.86.2.125 PubMed PMID: 10666406. doi: 10.1161/01.RES.86.2.125.
39. Marso SP, Mak KH, Topol EJ. Diabetes mellitus: biological determinants of atherosclerosis and restenosis. Semin Interv Cardiol 1999;4(3):129-143. Available from: http://www.nlm.nih.gov/medlineplus/bloodsugar.html PubMed PMID: 10545619. doi: 10.1053/siic.1999.0086.
40. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. American Heart Journal 1999;138(5 Pt 1):346-352.
41. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26(1):57-65. Available from: http://ClinicalTrials.gov/search/term=7797776%20%5BPUBMED-IDS%5D PubMed PMID: 7797776. doi: 10.1016/0735-1097(95)00126-K.
42. Malmberg K. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal 2005;26(7):650-661. Available from: http://eurheartj.oupjournals.org/cgi/doi/10.1093/eurheartj/ehi199 PubMed PMID: 15728645. doi: 10.1093/eurheartj/ehi199.
43. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Critical Care Medicine 2003;31(2):359-366. Available from: http://dx.doi.org/10.1097/01.CCM.0000045568.12881.10 PubMed PMID: 12576937. doi: 10.1097/01.CCM.0000045568.12881.10.
44. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.. J Am Coll Cardiol 1998;32(3):584-589. Available from: http://www.nlm.nih.gov/medlineplus/diabetestype1.html PubMed PMID: 9741497. doi: 10.1016/S0735-1097(98)00286-1.
45. Hage C, Norhammar A, Grip L, Malmberg K, Sarkar N, Svane B, et al. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diabetes and Vascular Disease Research 2009;6(2):71-79. Available from: http://dvr.sagepub.com/cgi/doi/10.1177/1479164109336042 PubMed PMID: 20368196. doi: 10.1177/1479164109336042.
46. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidem. Drug Safe 2008;17(8):760-768. Available from: http://doi.wiley.com/10.1002/pds.1598 PubMed PMID: 18383443. doi: 10.1002/pds.1598.
47. Frye RL, August P, Brooks MM, Hardison RM, Kelsy SF, et al. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. N Engl J Med 2009;360(24):2503-2515. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0805796 doi: 10.1056/NEJMoa0805796.
48. Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. The American Journal of Cardiology 2004;93(11):1347-1350. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002914904002760 PubMed PMID: 15165912. doi: 10.1016/j.amjcard.2004.02.028.
49. Kapinya K, Nijjar PS, Stanek M, Amanullah A. Insulin-sensitizing antihyperglycaemic medications are associated with better outcome in patients with diabetes undergoing cardiac stress testing. Intern Med J 2007;38(4):259-264. Available from: http://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html PubMed PMID: 17725610. doi: 10.1111/j.1445-5994.2007.01480.x.
Supplementary files
Review
For citations:
Michurova M.S., Kononenko I.V., Smirnova O.M., Kalashnikov V.Yu. Effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus. Diabetes mellitus. 2014;17(1):34-40. (In Russ.) https://doi.org/10.14341/DM2014134-40
Views:
652
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
